Company: TXG
Filing Date: 2025-04-14
Form Type: DEF 14A
Source: 0001770787-25-000018
Chunk: 28

Company: 10x Genomics, Inc.
Filing Date: 2025-04-14
Form: DEF 14A
Chunk 28
---
 I     |     | Chief Executive Officer and Director             |
| Benjamin J. Hindson          |     |  50 |     | I     |     | Chief Scientific Officer, President and Director |
| John R. Stuelpnagel(1)(2)(3) |     |  67 |     | I     |     | Chairman of our Board of Directors               |
| Alan Mateo(4)                |     |  63 |     | II    |     | Director                                         |
| Kimberly J. Popovits(1)(2)   |     |  66 |     | II    |     | Director                                         |
| Sarah Teichmann              |     |  49 |     | II    |     | Director                                         |
| Sri Kosaraju(1)(3)           |     |  47 |     | III   |     | Director                                         |
| Shehnaaz Suliman(3)(4)       |     |  53 |     | III   |     | Director                                         |

(1) Member of our audit committee.

(2) Member of our compensation committee.

(3) Member of our mergers and acquisitions committee.

(4) Member of our nominating and corporate governance committee.

#### 10X GENOMICS, INC.232025 PROXY STATEMENT

#### Nominees
|                      |     | Sri Kosaraju has served on our board of directors since April 2019. Mr. Kosaraju has served as President and Chief Executive Officer of Inscripta since October 2020. In addition, Mr. Kosaraju has served on the board of Nevro Corp., a publicly traded medical device company, since August 2021. Previously, Mr. Kosaraju served as President of Penumbra, a publicly traded medical device company, from August 2019 to May 2020, Chief Financial Officer from May 2015 to November 2019 and as Head of Strategy from May 2015 to August 2019. Prior to joining Penumbra, he worked in investment banking for J.P. Morgan Securities LLC from 1999 to May 2015, where he held a variety of positions with successively greater responsibility, most recently Managing Director of Equity Capital Markets, Head of Healthcare Equity Capital Markets and co-Head of Technology, Media, Telecom Equity Capital Markets. Prior to entering J.P. Morgan’s equity capital markets group in 2006, Mr. Kosaraju